1. Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France.
- Author
-
Olivereau L, Nave V, Garcia S, Perceval M, Rabilloud M, Durieu I, and Reynaud Q
- Subjects
- Adult, Age Factors, Cost-Benefit Analysis, Drug Combinations, Female, Forced Expiratory Volume, France epidemiology, Homozygote, Humans, Male, Respiratory Function Tests methods, Respiratory Function Tests statistics & numerical data, Retrospective Studies, Treatment Outcome, Aminophenols economics, Aminophenols therapeutic use, Aminopyridines economics, Aminopyridines therapeutic use, Benzodioxoles economics, Benzodioxoles therapeutic use, Chloride Channel Agonists economics, Chloride Channel Agonists therapeutic use, Cystic Fibrosis drug therapy, Cystic Fibrosis economics, Cystic Fibrosis epidemiology, Cystic Fibrosis genetics, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Quinolones economics, Quinolones therapeutic use, Assessment of Medication Adherence
- Abstract
Background: Lumacaftor-ivacaftor combination is a promising treatment for cystic fibrosis (CF) patients homozygous for the F508del-CFTR mutation. Optimal adherence is essential to achieve full health outcomes benefits., Methods: This retrospective study used pharmacy refills data to calculate proportion of days covered (PDC). Adherence was defined as a PDC ≥80%. A logistic regression analysis was conducted to examine factors associated with medication adherence., Results: Ninety-six patients were included in the final cohort for analysis. The mean PDC was 96% ± 14 at 6 months, and 91% ± 17 at 12 months. The proportion of adherent patients was 89% and 83% at 6 and 12 months respectively. Age and ppFEV1 were found to affect medication adherence., Conclusions: Considering the medico-economic impact of CFTR modulator therapy, high adherence rates to lumacaftor-ivacaftor found in this study are encouraging., Competing Interests: Declaration of Competing Interest The authors declare that they have no conflicts of interests., (Copyright © 2019 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF